Effect of Sangrovit WS on Growth, Survival and Prevention of *Vibrio harveyi* in Rearing of Pacific White Shrimp (*Litopenaeus vannamei*)

Tirawat Rairat[1], Niti Chuchird[1] and Chalor Limsuwan[1]

ABSTRACT

These studies were conducted under laboratory conditions. In Experiment 1, postlarvae 12 (PL12) were stocked in 500-liter fiberglass tanks (25 ppt salinity) at a density of 50 PL/tank. Shrimp were fed four times daily with pelleted feed containing Sangrovit WS at 0, 100 and 200 ppm (in three replicates/treatment). After 60 days of dietary administration, shrimp fed with 100 ppm of Sangrovit WS had an average body weight of 6.69 ± 0.44 g, which was higher than those of shrimp fed with 200 ppm of Sangrovit WS (6.60 ± 0.21g) and the control group without Sangrovit WS (6.49 ± 0.42g). Shrimp fed with 200 ppm of Sangrovit WS had the highest survival rate at $79.33 \pm 10.26\%$, followed by those fed with 100 ppm of Sangrovit WS ($74.67 \pm 10.07\%$) and the control group without Sangrovit WS ($68.00 \pm 6.93\%$). In Experiment 2, 30 shrimp from each tank in Experiment 1 were randomly sampled and stocked in 12 x 500-L fiberglass tanks with four replicate tanks per treatment group. *Vibrio harveyi* was added into each tank to obtain final concentration of 103 CFU/ml. Each treatment group received the diets four times daily for 30 days. All water quality parameters were maintained as in Experiment 1. At the end of the trial, there was no difference among the average body weight and the survival rate of shrimp from the three experimental groups. The study on the total number of *Vibrio* spp. in intestine of shrimp revealed that shrimp fed with 200 ppm of Sangrovit WS had the lowest total number of *Vibrio* spp. in intestine throughout the feeding trial followed by the group fed with 100 ppm of Sangrovit WS and the control group without Sangrovit WS. The total number of bacteria in the intestine of shrimp fed with 200 ppm of Sangrovit WS was significantly lower than in the groups fed with 100 ppm of Sangrovit WS and the control group throughout the feeding trial. The anti-inflamatory property in the hepatopancreas of shrimp was observed in the group fed with 100 and 200 ppm of Sangrovit WS. This study revealed the benefit of Sangrovit WS in anti-inflamatory and antimicrobial activities in shrimp.

Keywords: Sangrovit WS, *Litopenaeus vannamei, Vibrio harveyi*

INTRODUCTION

Currently, Pacific white leg shrimp, *Litopenaeus vannamei,* native to the Pacific coast of Central and South America, is the major shrimp species cultured in China, Taiwan

---

[1]Aquaculture Business Research Center, Faculty of Fisheries, Kasetsart University, Bangkok 10900,Thailand

and Thailand (Limsuwan and Chanratchakool, 2004). Since 2010, shrimp farmers in Thailand have experienced the White Feces Syndrome followed by the Early Mortality Syndrome (EMS) in 2012. These diseases caused major economic losses among shrimp farmers throughout the country. Bacterial pathogen especially *Vibrio* group was reported to be the suspect agents causing mass mortalities (Somboon *et al.*, 2012; Munkongwongsiri *et al.*, 2013). Many scientists have attempted to solve the problems by using probiotic bacteria or organic acids to reduce the pathogenic bacteria in the gut of shrimp as the prevention methods (Nayak *et al.*, 2012; Walla *et al.*, 2012). Sangrovit WS is one of the natural plant feed additives extracted from plume poppy (*Macleaya cordata*). It contains 1.5 % sanguinarine, a plant alkaloid which has several pharmacological properties including anti-inflammatory (Chaturvedi *et al.*, 1997; Vrba *et al.*, 2004; Dvorák *et al.*, 2006; Niu *et al.*,2012, 2013) and antimicrobial (Nandi *et al.*, 1983; Dzink and Socransky, 1985; Newton *et al.*, 2002; Kosina *et al.*, 2010). Many studies exhibit the positive effect of Sangrovit on growth performance of animals such as poultry (Vieira *et al.*, 2008a, 2008b), tilapia (Rawling *et al.*, 2009) and sea bass (Korkut *et al.*, 2012). However, their use in shrimp is new. The aim of this study is to evaluate the effect of Sangrovit WS on survival and growth of shrimp. The possibility of Sangrovit WS to prevent *Vibrio harveyi* infection in shrimp is also evaluated.

MATERIALS AND METHODS

Experiment 1-The effects of Sangrovit WS on growth and survival of Pacific white shrimp postlarvae

Experimental diets

Three experimental diets were formulated for the present study. Commercial pellet feed without Sangrovit WS was used as control; the other two diets were pellet feed mixed with 100 and 200 mg Sangrovit WS/1 kg of feed. Sangrovit WS for each treatment was applied by dissolving Sangrovit WS powder in distilled water, then spraying and mixing it with commercial pellet feed to obtain a final concentration of 100 and 200 ppm.

Shrimp and experimental protocol

The experiments were carried out at the Aquaculture Business Research Center Laboratory, Faculty of Fisheries, Kasetsart University, Thailand. Postlarvae 9 (PL-9) Pacific white shrimp were obtained from a hatchery in Chachoengsao Province, Thailand. After three days of acclimation, 450 postlarvae (now at PL-12 stage) were randomly distributed into 9 x 500-L fiberglass tanks (three replicate tanks per treatment). Each tank was stocked at a density of 50 PLs per tank to achieve a density of 100 PLs/m^2. Each treatment group was fed with the aforementioned diet four times daily for 60 days. Salinity throughout the experiment was maintained at 25 ppt, dissolved oxygen above 4 ppm, and water temperature at 29±1°C.

Growth and survival studies

Ten PLs from each tank were randomly selected and weighed at days 30, 40, 50, and 60 to determine growth. Surviving shrimp were counted on the 60th day and survival rate was calculated using the formula: survival rate (%) = (survival shrimps/total shrimps at 0 day) x 100.

Experiment 2-The effects of Sangrovit WS on growth, survival, and intestinal bacteria of Pacific white shrimps challenged with *Vibrio harveyi*

Shrimp and experimental protocol

Shrimp from Experiment 1 were fed with the same diet for another 10 days until they reached 10 - 12 g. Then they were randomly distributed into 12 x 500-L fiberglass tanks (four replicate tanks per treatment). Each tank was stocked at a density of 30 shrimp per tank. At the beginning of this experiment (Day 0), *Vibrio harveyi* was added into each tank to obtain a final concentration of 10^3 CFU/ml. Each treatment group received the aforementioned diets four times daily for another 30 days. Salinity, dissolved oxygen, and water temperature were maintained as in Experiment 1.

Three tanks from each group were used for growth and survival studies. Another tank from each group was used for intestinal bacterial and histopathological studies.

Growth and survival studies

Ten shrimps from each tank were randomly selected and weighed on days 10, 20, and 30, to determine growth. Surviving shrimps were also counted on these days and survival rate was calculated using the formula: survival rate (%) = (survival shrimps/total shrimps at 0 day) x 100.

Intestinal bacterial study

Five shrimps from each group were randomly selected and their intestine collected on the days 10, 20, and 30. Intestine of each shrimp was homogenized and spread on TCBS (selective media for *Vibrio* spp. culture) or NA (general media for most bacteria culture), then incubated at 37°C for 24 hours. All colonies of bacteria were counted and calculated to CFU/g unit.

Histopathological study

Five shrimps from each group were randomly selected and fixed in Davidson's fixative for 48 hours, 30 days after immersion with *Vibrio harveyi* 10^3 CFU/ml. All shrimp samples were processed for histopathological study of hepatopancreas and intestine as described by Bell and Lightner (1988).

Statistical analysis

Data were analyzed using the software SPSS v 11.5. One way ANOVA and Duncan's New Multiple Range test were used to compare data among treatments. Differences were considered significant if P<0.05.

RESULTS

Experiment 1-The effects of Sangrovit WS on growth and survival of Pacific white shrimp postlarvae

After 60 days of the feeding trial, shrimp fed with 100 ppm of Sangrovit WS had the highest average body weight of 6.69 ± 0.44 g, followed by 6.60 ± 0.21 g from the group fed with 200 ppm of Sangrovit WS, and 6.49 ± 0.42 g from the control group without Sangrovit WS (Table 1).

Table 1. The body weight (g) of Pacific white shrimp after 60 days of feeding with 100 and 200 ppm of Sangrovit WS

Groups	Day 30	Day 40	Day 50	Day 60
Control	1.35 ± 0.22^a	3.35 ± 0.22^a	5.25 ± 0.23^a	6.49 ± 0.42^a
100 ppm Sangrovit	1.77 ± 0.10^a	3.58 ± 0.32^a	5.27 ± 0.35^a	6.69 ± 0.44^a
200 ppm Sangrovit	1.63 ± 0.30^a	3.57 ± 0.11^a	5.30 ± 0.26^a	6.60 ± 0.21^a

Data are presented as means ± standard deviation. Means in the same column with different superscripts are significantly different from each other (P<0.05)

At the end of the feeding trial, shrimp in the group fed with 200 ppm of Sangrovit WS showed the highest average percentage survival rate of 79.33 ± 10.26%, followed by the group fed with 100 ppm of Sangrovit WS which had a 74.67 ± 10.07% survival. The average survival rate of these two groups was higher than that of the control group without Sangrovit WS (68.00 ± 6.93%) (Table 2).

Table 2. Survival rates(%) of Pacific white shrimp after 60 days of feeding with 100 and 200 ppm of Sangrovit WS

Groups	Day 0	Day 60
Control	$100.00 + 0.00^a$	68.00 ± 6.93^a
100 ppm Sangrovit	$100.00 + 0.00^a$	74.67 ± 10.07^a
200 ppm Sangrovit	$100.00 + 0.00^a$	79.33 ± 10.26^a

Data are presented as means ± standard deviation. Means in the same column with different superscripts are significantly different from each other (P<0.05)

Experiment 2-The effects of Sangrovit WS on growth, survival, and intestinal bacteria of Pacific white shrimps challenged with *Vibrio harveyi*

After 70 days of feeding trial and another 30 days of exposure to 10^3 CFU/ml of *V. harveyi* with the same feeding regimen, shrimp given feed mixed with 200 ppm of Sangrovit WS showed the highest average body weight of 16.34 ± 0.78 g which was higher than the groups given feed mixed with 100 ppm of Sangrovit WS (average body weight of 16.10 ± 0.72 g) and the control group (average body weight of 16.16 ± 0.18 g) (Table 3).

Table 3. The body weights (g) of Pacific white shrimp after 30 days of exposure to 10^3 CFU/ml *Vibrio harveyi*

Groups	Day 0	Day 10	Day 20	Day 30
Control	10.55 ± 0.21^a	13.09 ± 1.05^a	14.40 ± 0.21^a	16.16 ± 0.18^a
100 ppm Sangrovit	11.47 ± 1.22^a	13.89 ± 0.41^a	14.36 ± 0.76^a	16.10 ± 0.72^a
200 ppm Sangrovit	10.22 ± 0.54^a	12.87 ± 0.31^a	13.95 ± 0.09^a	16.34 ± 0.78^a

Data are presented as means ± standard deviation. Means in the same column with different superscripts are significantly different from each other (P<0.05)

The percentage survival rates of shrimp after the 30 days challenge with *V. harveyi* at 10^3 CFU/ml and fed with the same feeding regimen, are presented in Table 4. Shrimp fed 200 ppm of Sangrovit WS had the highest percentage survival rate of 71.11 ± 11.71 %, followed by the group fed 100 ppm of Sangrovit WS and the control group which had the average percentage survival rate of 68.89±10.72% and 66.67±8.82%, respectively.

Table 4. Survival rates (%) of Pacific white shrimp after being challenged with 10^3 CFU/ml *Vibrio harveyi* and feeding with 100 and 200 ppm of Sangrovit WS for 30 days

Groups	Day 0	Day 10	Day 20	Day 30
Control	100.00 ± 0.00^a	98.89 ± 1.92^a	76.67 ± 8.82^a	66.67 ± 8.82^a
100 ppm Sangrovit	100.00 ± 0.00^a	96.67 ± 3.33^a	77.78 ± 10.18^a	68.89 ± 10.72^a
200 ppm Sangrovit	100.00 ± 0.00^a	100.00 ± 0.00^a	81.11 ± 5.09^a	71.11 ± 11.71^a

Data are presented as means ± standard deviation. Means in the same column with different superscripts are significantly different from each other (P<0.05)

The total number of *Vibrio* spp. in intestine of experimental shrimp after the 30 days challenge with *V. harveyi* at 10^3 CFU/ml following the same feeding regimen as in Experiment 1, is shown in Table 5. Shrimp fed with 200 ppm of Sangrovit WS had the lowest total number of *Vibrio* spp. in intestine throughout the feeding trial. The total number of *Vibrio* spp. in the intestine of this group was lower than the groups fed with 100 ppm of Sangrovit WS and the control group.

Table 5. Total number of *Vibrio* spp. (10^4 CFU/g) in the intestine of Pacific white shrimp after exposure to 10^3 CFU/ml *Vibrio harveyi* for 30 days

Groups	Day 0	Day 10	Day 20	Day 30
Control	4.79 ± 1.45^a	8.64 ± 2.54^b	6.68 ± 2.79^b	3.41 ± 1.41^a
100 ppm Sangrovit	4.71 ± 1.74^a	5.37 ± 2.27^a	3.03 ± 1.74^a	2.31 ± 1.35^a
200 ppm Sangrovit	4.69 ± 1.87^a	4.82 ± 1.35^a	3.05 ± 1.11^a	1.52 ± 1.20^a

Data are presented as means ± standard deviation. Means in the same column with different superscripts are significantly different from each other (P<0.05)

The total number of bacteria in the intestine of shrimp after the 60 days feeding trial (Experiment 1) and 30 days challenge with *V. harveyi* at 10^3 CFU/ml (Experiment 2) are shown in Table 6. Shrimp fed with 200 ppm of Sangrovit WS had the lowest total number of bacteria in intestine throughout the experiment. The total number of bacteria in intestine of shrimp in this group was significantly lower than the groups fed with 100 ppm of Sangrovit WS and the control group throughout the feeding trial.

Table 6. Total number of bacteria (10^4 CFU/g) in the intestine of Pacific white shrimp after challenge with 10^3 CFU/ml *Vibrio harveyi* for 30 days

Groups	Day 0	Day 10	Day 20	Day 30
Control	14.79 ± 6.10^a	77.65 ± 20.33^b	38.65 ± 15.05^b	22.83 ± 8.89^b
100 ppm Sangrovit	14.81 ± 5.01^a	49.56 ± 30.11^{ab}	27.34 ± 8.41^b	15.47 ± 5.23^{ab}
200 ppm Sangrovit	14.85 ± 5.40^a	32.36 ± 7.85^a	12.38 ± 7.16^a	13.05 ± 3.43^a

Data are presented as means ± standard deviation. Means in the same column with different superscripts are significantly different from each other (P<0.05)

Histopathology of experimental shrimp

Histopathological study of the hepatopancreas of shrimp revealed signs of mild bacterial infection only in the control group (Figure 7A,7B), while hepatopancreas of shrimp in the group fed with 100 and 200 ppm of Sangrovit WS appeared normal (Figures 8A, 8B,9A,9B, respectively). Some shrimp in the control group showed signs of lightly bacterial infection including granulomatous lesions, necrosis of hepatopancreatic cells accompanied by hemocytic infiltration. Whereas the histopathological study of intestines of shrimp from all groups showed no sign of bacterial infection (Figures 7C, 7D, 8C, 8D, 9C, 9D).


Figure 7. (A, B) Hepatopancreas of control shrimp with granulomatous lesions (arrows) accompanied by hemocytic infiltration among normal tissues (100x); (C) Intestine (cross section) of control shrimp with normal appearance (400x); (D) Intestine (longitudinal section) of control shrimp with normal appearance (400x).

Figure 8. (A, B):Hepatopancreas of 100 ppm Sangrovit WS-fed shrimps with normal appearance (50x & 100x); (C) Intestine (cross section) of 100 ppm Sangrovit WS-fed shrimps with normal appearance (400x); (D) Intestine (longitudinal section) of 100 ppm Sangrovit WS -fed shrimps with normal appearance (400x).


Figure 9. (A, B) Hepatopancreas of 200 ppm Sangrovit WS-fed shrimps with normal appearance (50x & 100x); (C) Intestine (cross section) of 200 ppm Sangrovit WS-fed shrimps with normal appearance (400x); (D) Intestine (longitudinal section) of 200 ppm Sangrovit WS -fed shrimps with normal appearance (400x).

DISCUSSION

Despite several studies showing the positive effect of Sangrovit WS on the health of many vertebrate animals (Rawling *et al.*, 2009; Korkut *et al.*, 2012), no such data is available for shrimp.

In the aspect of growth promotion, Sangrovit's active ingredient, sanguinarine, has two important pharmacological properties, namely anti-inflamatory and anti-microbial, similar to those of antibiotic growth promoters (AGPs), especially cycline and macrolide groups, which have been proposed for growth enhancement of AGPs (Dibner and Richards, 2005; Niewold, 2007; Modi *et al.*, 2011). Consequently, the growth-promoting effect of sanguinarine caused by these mechanisms is possible. However, Sangrovit WS showed neither positive nor negative effect on shrimp's growth, determined by body weight, and survival rate in the present study. This may be a consequence of losing some Sangrovit WS from the surface of pelleted feeds due to the high solubility of Sangrovit WS. So the actual dose of Sangrovit WS in shrimp diets may be lower than the expected dose which obscured the growth-promoting effect.

However, the antimicrobial activity of Sangrovit WS in this study was visible. Sangrovit WS could reduce a number of bacterials, both *Vibrio* spp. and total bacteria, in the intestine of shrimp, especially on days 10 and 20 after being challenged with *V. harveyi*. These results are likely due to the antimicrobial property of sanguinarine alkaloid, by two possible mechanisms of action, namely compromising microbial cytoplasmic membrane (Obiang-Obounou *et al.*, 2011) or perturbing FtsZ assembly dynamics in the Z ring which resulted in bacterial cytokinesis inhibition (Beuria *et al.*, 2005). The ability of Sangrovit to reduce pathogenic bacteria in the intestine of animals was also reported by Gharib Naseri *et al.* (2012).

The histopathological study showed a slight difference in the appearance of hepatopancreas between the control group and Sangrovit WS-fed groups. The hepatopancreas of shrimp in the control group had a few granulomatous lesions as a result of *V. harveyi* infection similar to the results obtained by Jiravanichpaisala *et al.* (1994). However, the normal histopathology of the hepatopancreas of the Sangrovit WS-fed groups could be a results of the anti-inflamatory property of sanguinarine, as reported in other studies (Chaturvedi *et al.*, 1997; Vrba *et al.*, 2004; Dvorák *et al.*, 2006; Niu *et al.*, 2012, 2013). Moreover, the anti-inflammatory effect of Sangrovit in the present study was consistent with a recent study by Vrublová *et al.*, (2010). Meanwhile, the histopathological study of the intestines of shrimp from all groups showed no sign of bacterial infection. This may be because of the low number of *V. harveyi* in the water. The quantities of *Vibrio* spp. in the intestine of all groups on the final day were not significantly different from each other.

In conclusion, this study revealed that Sangrovit WS could reduce the total number of bacteria in the intestine of shrimp. However, the effect on the growth and survival rate of shrimp was unclear. The benefit of using Sangrovit WS as anti-inflamatory in shrimp or as an alternative to antibiotics for the control pathogenic bacterial infection is promising.

ACKNOWLEDGEMENT

LITERATURE CITED

Bell, T.A. and D.V. Lightner.1988. **A Handbook of Normal Penaeid Shrimp Histology.** World Aquaculture Society, Baton Rouge, Louisiana.114 pp.

Beuria, T.K., M.K. Santra and D. Panda.2005. Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling. **Biochemistry** 44 (50): 16584-16593.

Chaturvedi, M.M., A. Kumar, B.G. Darnay, G.B. Chainy, S. Agarwal and B.B. Aggarwal. 1997. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-κB activation, IκBα phosphorylation, and degradation. **J Biol Chem** 272 (48): 30129-30134.

Dibner, J.J and J.D. Richards.2005. Antibiotic growth promoters in agriculture: history and mode of action. **Poult Sci** 84 (4): 634-643.

Dvorák, Z., R. Vrzal, P. Maurel and J. Ulrichová. 2006. Differential effects of selected natural compounds with anti-inflammatory activity on the glucocorticoid receptor and NF-κB in HeLa cells. **Chem Biol Interact** 159 (2): 117-128.

Dzink, J.L. and S.S. Socransky.1985. Comparative *in vitro* activity of sanguinarine against oral microbial isolates. **Antimicrob Agents Chemother** 27 (4): 663-635.

GharibNaseri, K., S. Rahimi and P. Khaki. 2012. Comparison of the Effects of Probiotic, Organic Acid and Medicinal Plant on *Campylobacter jejuni* Challenged Broiler Chickens. **J Agr Sci Tech** 14: 1485-1496.

Jiravanichpaisala, P., T. Miyazakia and C. Limsuwan. 1994. Histopathology, Biochemistry, and Pathogenicity of *Vibrio harveyi* Infecting Black Tiger Prawn *Penaeus monodon*. **J Aquat Anim Health** 6 (1): 27 -35.

Korkut, A.Y., A. Kop and M. Düngelhoef. 2012. **Effect of Sangrovit® on the growth and performance of sea bass (*Dicentrarchus labrax* L., 1758).** Available Source: http://www.efeedlink. com/CPS/attachment/2012/March/ 2012051820492790411354.pdf, October 27, 2012.

Kosina, P., D. Walterová, J. Ulrichová, V. Lichnovský, M. Stiborová, H. Rýdlová, J. Vicar, V. Krecman, M.J. Brabec and V. Simánek. 2004. Sanguinarine and chelerythrine: assessment of safety on pigs in ninety days feeding experiment. **Food ChemToxicol** 42 (1): 85-91.

Kosina, P., Gregorova, J. Gruz, J. Vacek, M. Kolar, M. Vogel, W. Roos, K. Naumann, V. Simanek and J. Ulrichova. 2010. Phytochemical and antimicrobial characterization of *Macleaya cordata* herb. **Fitoterapia** 81 (8): 1006-1012.

Limsuwan, C. and P. Chanratchakool. 2004. **Shrimp Aquaculture Industries of Thailand.** National Research Council of Thailand.206 pp.

Modi, C.M., S.K. Mody, H.B. Patel, G.B. Dudhatra, Avinash Kumar and T.J. Sheikh. 2011. Growth promoting use of antimicrobial agents in animals. **J Pharm Sci** 01(08): 33-36.

Munkongwongsiri, N., C. Limsuwan and N. Chuchird. 2013. Effects of Postlarval Quality on Occurrence of Early Mortality Syndrome in *Litopenaeus vannamei* Culture Ponds, pp. 174-181. *In* **Proceeding of 51ᵗʰ Kasetsart University Annual Conference, Fisheries section.** Kasetsart University, Bangkok, Thailand.

Nandi, R., M. Maiti, K. Chaudhuri, S.B. Mahato and A.K. Bairagi. 1983. Sensitivity of vibrios to sanguinarine. **Experientia** 39 (5): 524-525.

Nayak, S., C. Limsuwan, N. Chuchird, and S. Pungpang. 2012. A Study on the Effect of *Bacillus* spp. to Control the Pathogenic Bacteria in Aquaculture. **KU Fish Res Bull** 36 (2): 1-13.

Newton, S.M., C. Lau, S.S. Gurcha, G.S. Besra and C.W. Wright. 2002. The evaluation of forty-three plant species for *in vitro* antimycobacterial activities; isolation of active constituents from *Psoralea corylifolia* and *Sanguinaria canadensis.* **J Ethnopharmacol** 79 (1): 57-67.

Niewold, T.A. 2007. The nonantibiotic anti-inflammatory effect of antimicrobial growth promoters, the real mode of action? A hypothesis. **Poult Sci** 86 (4): 605-609.

Niu, X., T. Fan, W. Li, W. Xing and H. Huang. 2012. The anti-inflammatory effects of sanguinarine and its modulation of inflammatory mediators from peritoneal macrophages. **Eur J Pharmacol**

689 (1-3): 262-9.

Niu, X., T. Fan, W. Li, H. Huang, Y. Zhang and W. Xing. 2013. Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice. **Toxicol Appl Pharmacol** 267 (3): 256-265.

Obiang-Obounou, B.W., O.H. Kang, J.G. Choi, J.H. Keum, S.B. Kim, S.H. Mun, D.W. Shin, K.W. Kim, C.B. Park, Y.G. Kim, S.H. Han and D.Y. Kwon. 2011. The mechanism of action of sanguinarine against methicillin-resistant *Staphylococcus aureus*. **J Toxicol Sci** 36 (3): 277-83.

Psotova, J., R. Vecera, A. Zdarilova, E. Anzenbacherova, P. Kosina, A. Svobodova, J. Hrbac, D. Jirovsky, M. Stiborova, V. Lichnovsky, J. Vicar, J. Simanek and J. Ulrichova. 2006b. Safety assessment of sanguiritrin, alkaloid fraction of *Macleaya cordata*, in rats.**Vet Med** 51 (4): 145-155.

Rawling M.D., D.L. Merrifield and S.J. Davies. 2009. Preliminary assessment of dietary supplementation of Sangrovit® on red tilapia (*Oreochromis niloticus*) growth performance and health. **Aquaculture** 294 (1-2): 118–122.

Somboon, M., W. Purivirojkul, C. Limsuwan and N. Chuchird. 2012. Effect of *Vibrio* spp. in white feces infected shrimp in Chanthaburi, Thailand. **KU Fish Res Bull** 36 (1): 7-15.

Vieira, S.L., J. Berres, R.N. Reis, O.A. Oyarzabal, J.L.B. Coneglian, D.M. Freitas, J.E.M. Peña and C.A. Torres. 2008a. Studies with sanguinarine like alkaloids as feed additive in broiler diets. **Rev Bras Cienc Avic** 10 (1): 67-71.

Vieira, S.L., O.A. Oyarzabal, D.M. Freitas, J. Berres, J.E.M. Peña, C.A. Torres, and J.L.B. Coneglian. 2008b. Performance of Broilers Fed Diets Supplemented with Sanguinarine-Like Alkaloids and Organic Acids. **J Appl Poult Res** 17 (1): 128-133.

Vrba, J., J. Hrbác, J. Ulrichová and M. Modrianský. 2004. Sanguinarine is a potent inhibitor of oxidative burst in DMSO-differentiated HL-60 cells by a non-redox mechanism. **Chem Biol Interact** 147 (1): 35-47.

Vrublová, E., J. Vostálová, J. Ehrmann, I. Palíková, J. Vrbková, J. Vacek, N. Cibíček, R. Večeřa, J. Ulrichová and V. Šimánek. 2010. The phytogenic feed additive Sangrovit modulates dextran sulfate sodium-induced colitis in rats. **Vet Med** 55 (12): 610-618.

Walla, W., W. Purivirojkul, N. Chuchird and C. Limsuwan. 2012. Effect of Activate DA on Growth, Survival and the Total Number of Bacteria and *Vibrio* spp. in Rearing of Pacific White Shrimp (*Litopenaeus vannamei*). **KU Fish Res Bull** 36 (2): 14-22.